Text of section effective on April 01, 2025
Sec. 549.0105.  REQUIRED DISCLOSURES IN NEGOTIATIONS FOR SUPPLEMENTAL REBATES.  Before or during supplemental rebate agreement negotiations for a prescription drug being considered for the preferred drug list, the commission shall disclose to pharmaceutical manufacturers any clinical edits or clinical protocols that may be imposed on drugs within a particular drug category that are placed on the preferred drug list during the contract period.  Clinical edits may not be imposed for a preferred drug during the contract period unless the disclosure is made.
Added by Acts 2023, 88th Leg., R.S., Ch. 769 (H.B. 4611), Sec. 1.01, eff. April 1, 2025.